GSK3B and cancer: SLFN5 downregulates membrane type 1 matrix metalloproteinase (MT1-MMP) expression through the AKT/GSK-3β/β-catenin pathway in several types of cancer cells, exerting inhibitory effects on migration and invasion (17).